What is Zai Lab Limited - ADR Annual Revenue?

Zai Lab Limited - ADR Annual Revenue rose 49.59%, in the last year to $398.99 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

What is Zai Lab Limited - ADR Annual Net Profit?

Zai Lab Limited - ADR Annual Net Profit rose 23.17% in the last year to $257.1 M. Its sector's average net profit growth for the last fiscal year was -32.43%.

What is Zai Lab Limited - ADR Price to Earning Ratio?

Zai Lab Limited - ADR Price to Earning Ratio is -14.78, which is negative.

What is Zai Lab Limited - ADR Stock Price?

Zai Lab Limited - ADR Stock Price rose 116.87% and outperformed its sector by 107.8% in the past year.

What is Zai Lab Limited - ADR Quarterly Revenue?

Zai Lab Limited - ADR Quarterly Revenue rose 65.68% YoY to $109.07 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

What is Zai Lab Limited - ADR Quarterly Net profit?

Zai Lab Limited - ADR Quarterly Net profit rose 14.4% YoY to $81.68 M. Its sector's average net profit growth YoY for the quarter was -47.3%.

What is Zai Lab Limited - ADR Debt to Equity Ratio?

Zai Lab Limited - ADR Debt to Equity Ratio of 0.18 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Zai Lab Limited - ADR Return on Equity(ROE)?

Zai Lab Limited - ADR Return on Equity(ROE) for the last financial year was -31.41%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Zai Lab Limited - ADR Mutual Fund Holding?

Zai Lab Limited - ADR Mutual Fund Holding increased by 0.53% in the last quarter to 43.06.

What is Zai Lab Limited - ADR Promoter Share Holding?

Zai Lab Limited - ADR Promoter Share Holding decreased by 0.12% in the most recent quarter to 2.72%.

What is Zai Lab Limited - ADR Interest Coverage Ratio?

Zai Lab Limited - ADR Interest Coverage Ratio is -113.07, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Zai Lab Limited - ADR Institutional Holding?

Zai Lab Limited - ADR Institutional Holding remained the same in the last quarter at 53.98%.

How is the Zai Lab Limited - ADR today?

The Zai Lab Limited - ADR today is trading in the down by -6.00% at 35.09.

How has Zai Lab Limited - ADR performed historically?

The Zai Lab Limited - ADR is currently trading down -6.00% on an intraday basis in the past week the index fell -8.14%. The index has been up 31.32% in the past quarter and rose 116.87% in the past year. You can view this in the overview section.

Zai Lab Limited - ADR XNAS: ZLAB

Zai Lab Limited - ADR Live Share Price Today, Share Analysis and Chart

Name: Zai Lab Limited - ADR: Is Infosys Ltd. worth buying?
Item: Zai Lab Limited - ADR
Rating: 1.224819375
Author: Trendlyne DVM scores

Momentum Trap

Download real time

35.09 -2.24 (-6.00%)

160.31% Gain from 52W Low

797.5K XNAS Volume

XNAS 21 Mar, 2025 5:30 PM (EDT)

Zai Lab Limited - ADR Key Metrics

My Metrics

Select

Market Capitalization High in industry Unavailable in chosen country	3,799.4
PE TTM Negative PE TTM Unavailable in chosen country	-14.8
PEG TTM Negative PEG TTM Unavailable in chosen country	-0.6
Price to Book Below industry Median Unavailable in chosen country	4.5
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	54
Revenue Growth Qtr YoY % Below industry Median Unavailable in chosen country	65.7
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	49.6
Net Profit Qtr Growth YoY % Below industry Median Unavailable in chosen country	14.4
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	23.2
Operating Profit Margin Qtr % Negative Operating Profit Margin Qtr % Unavailable in chosen country	-61.3
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-69.4
Piotroski Score Low in industry Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	22.7
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-31.4
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-23.1

All financials are in USD Million and price data in USD

Low Financial Strength

11.1 / 100

Expensive Valuation

10.3 / 100

Technically Moderately Bullish

65.4 / 100

Momentum Trap These stocks are with a bad quality and poor financial score ranging from medium to expensive valuation. Rising technical aspects may attract investors, but, weak financials cannot be overlooked. View Similar Embed DVM

1Yr Price target upside is 57%

10 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Zai Lab Limited - ADR Stock Price Analysis

Day Price Range -6.0% 1 Day return Unavailable in chosen country	35.1 (LTP) 34.735.8 LowHigh
Week Price Range -8.1% 1 Week return Unavailable in chosen country	35.1 (LTP) 34.738.6 LowHigh
Month Price Range 3.9% 1 Month return Unavailable in chosen country	35.1 (LTP) 31.339.6 LowHigh
52 Week Price Range 116.9% 1 Year return Unavailable in chosen country	35.1 (LTP) 13.539.6 LowHigh

View full Share Price History

Zai Lab Limited - ADR Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Miss

Zai Lab Limited - ADR's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-2.6

Avg. Estimate

-1.6

Low Estimate

-2.1

High Estimate

-1.3

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 39.2% in FY25

Consensus Recommendation

11 ANALYST Recommendations

STRONG BUY

The consensus recommendation from 11 analysts for Zai Lab Limited - ADR is STRONG BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Zai Lab Limited - ADR Stock Analysis

Zai Lab Limited - ADR stock analysis with key metrics, changes, and trends.

Zai Lab Limited - ADR Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$398.99 M	49.59%	positive	Annual Revenue rose 49.59%, in the last year to $398.99 M. Its sector's average revenue growth for the last fiscal year was 7.46%.
Annual Net Profit	$257.1 M	23.17%	positive	Annual Net Profit rose 23.17% in the last year to $257.1 M. Its sector's average net profit growth for the last fiscal year was -32.43%.
Price to Earning Ratio	-14.78	-	negative	Price to Earning Ratio is -14.78, which is negative.
Stock Price	$35.09	116.87%	positive	Stock Price rose 116.87% and outperformed its sector by 107.8% in the past year.
Quarterly Revenue	$109.07 M	65.68%	positive	Quarterly Revenue rose 65.68% YoY to $109.07 M. Its sector's average revenue growth YoY for the quarter was 5.96%.
Quarterly Net profit	$81.68 M	14.4%	positive	Quarterly Net profit rose 14.4% YoY to $81.68 M. Its sector's average net profit growth YoY for the quarter was -47.3%.
Debt to Equity Ratio	0.18	-	positive	Debt to Equity Ratio of 0.18 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-31.41 %	-31.41%	negative	Return on Equity(ROE) for the last financial year was -31.41%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	43.06 %	0.53%	positive	Mutual Fund Holding increased by 0.53% in the last quarter to 43.06.
Promoter Share Holding	2.72 %	-0.12%	negative	Promoter Share Holding decreased by 0.12% in the most recent quarter to 2.72%.
Interest Coverage Ratio	-113.07	-	negative	Interest Coverage Ratio is -113.07, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).
Institutional Holding	53.98 %	0%	neutral	Institutional Holding remained the same in the last quarter at 53.98%.

VIEW LESS

Loading data..

Zai Lab Limited - ADR - Company Profile

What does Zai Lab Limited - ADR do?

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Gross Remuneration

2024

Gross Remuneration

Year

Zai Lab Limited - ADR Live Share Price Today, Share Analysis and Chart

160.31% Gain from 52W Low

Zai Lab Limited - ADR Key Metrics

Market Capitalization

PE TTM

PEG TTM

Rel Perf vs Sector quarter%

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

ROE Annual %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

RoA Annual %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Zai Lab Limited - ADR Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Zai Lab Limited - ADR Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Zai Lab Limited - ADR's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

EPS is expected to grow by 39.2% in FY25

Consensus Recommendation

The consensus recommendation from 11 analysts for Zai Lab Limited - ADR is STRONG BUY

Zai Lab Limited - ADR Stock Analysis

Zai Lab Limited - ADR stock analysis with key metrics, changes, and trends.

Annual Revenue rose 49.59%, in the last year to $398.99 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

Annual Net Profit rose 23.17% in the last year to $257.1 M. Its sector's average net profit growth for the last fiscal year was -32.43%.

Price to Earning Ratio is -14.78, which is negative.

Stock Price rose 116.87% and outperformed its sector by 107.8% in the past year.

Quarterly Revenue rose 65.68% YoY to $109.07 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

Quarterly Net profit rose 14.4% YoY to $81.68 M. Its sector's average net profit growth YoY for the quarter was -47.3%.

Debt to Equity Ratio of 0.18 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -31.41%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 0.53% in the last quarter to 43.06.

Promoter Share Holding decreased by 0.12% in the most recent quarter to 2.72%.

Interest Coverage Ratio is -113.07, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding remained the same in the last quarter at 53.98%.

Zai Lab Limited - ADR - Company Profile

What does Zai Lab Limited - ADR do?

Zai Lab Limited - ADR Management structure

Dr. Harald Reinhart, M.D.

President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases

Dr. Samantha Du

Chairwoman of the Board and Chief Executive Officer

Dr. Yajing Chen

Chief Financial Officer and Principal Accounting Officer

Zai Lab Limited - ADR Board of directors

Dr. John D. Diekman,PhD

Lead Independent Director

Mr. Leon O. Moulder, Jr

Independent Director

Mr. Peter Wirth, J.D.

Independent Director

Mr. William Lis